Journal
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
Volume 9, Issue 4, Pages 503-512Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756283X16647935
Keywords
anti-integrins; etrolizumab; inflammatory bowel disease; ulcerative colitis
Categories
Ask authors/readers for more resources
Antiadhesion molecules are effective and safe in patients with ulcerative colitis (UC). Etrolizumab, a monoclonal antibody targeting both (47) and (E7), represents a promising therapy for patients with UC, since this novel mechanism of action may be effective in blocking leukocyte recruitment both at the vascular and at the mucosal level. Preliminary studies show that etrolizumab is effective in inducing clinical response and remission, and mucosal healing. Moreover, new predictors of response have recently been identified, opening the way to a tailored therapeutic approach. This review of the literature aims to present and discuss the most recent evidence on etrolizumab in UC, focusing on the clinical implications of the use of etrolizumab in UC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available